文献速递消化系统肿瘤支持与姑息治疗

胰腺导管腺癌的多学科诊疗标准与近期进展

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.
PubMed 文献 · CA Cancer J Clin · 2020-07-19

本文综述胰腺导管腺癌的多学科诊疗标准,指出该病预后差主要因发现延迟和系统治疗疗效有限,近十年发病率和死亡率均上升。可切除患者的多模式治疗显著改善总生存、局部控制和无转移生存,而可切除与不可切除/转移患者间预后差距扩大,强调早期发现的重要性。靶向肿瘤特异性分子弱点的治疗有望改善晚期疾病控制,但消瘦、疲乏和疼痛等 morbidity 仍未被充分关注。

要点

  • 胰腺癌发病率和死亡率近十年均上升,与多数实体瘤趋势相反。
  • 可切除患者的多模式治疗显著改善总生存、局部控制和無转移生存。
  • 可切除与不可切除/转移患者预后差距扩大,凸显早期发现的重要性。

核心结论

  • 胰腺导管腺癌预后仍很差,主要因发现延迟和系统治疗疗效有限。
  • 可切除患者的多模式治疗显著改善总生存、局部控制和無转移生存。
  • 靶向肿瘤特异性分子弱点的治疗可能改善晚期疾病控制。

研究设计与样本

  • 本文为综述,回顾胰腺癌当前多学科诊疗标准,聚焦检测、精准治疗和生存者管理的新概念。

主要发现

  • 近十年胰腺癌发病率和死亡率均上升,与多数其他实体瘤类型相反。
  • 可切除与不可切除或转移性胰腺癌患者之间的预后差距正在扩大。
  • 消瘦、疲乏和疼痛等 substantial morbidity 仍是未充分解决的组成部分,影响生活质量和积极治疗耐受性。

临床怎么用

  • 对可切除胰腺癌应采用多模式治疗以改善总生存、局部控制和無转移生存。
  • 应重视早期检测以缩小可切除与不可切除/转移患者间的预后差距。
  • 对晚期患者可考虑针对肿瘤特异性分子弱点的精准治疗。
  • 需关注并管理消瘦、疲乏和疼痛等 morbidity,以改善生活质量和治疗耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer, the prognosis for this disease remains very poor, largely because of delayed disease detection and limited effectiveness of systemic therapies. Both incidence rates and mortality rates for pancreatic cancer have increased during the past decade, in contrast to most other solid tumor types. Recent improvements in multimodality care have substantially improved overall survival, local control, and metastasis-free survival for patients who have localized tumors that are amenable to surgical resection. The widening gap in prognosis between patients with resectable and unresectable or metastatic disease reinforces the importance of detecting pancreatic cancer sooner to improve outcomes. Furthermore, the developing use of therapies that target tumor-specific molecular vulnerabilities may offer improved disease control for patients with advanced disease. Finally, the substantial morbidity associated with pancreatic cancer, including wasting, fatigue, and pain, remains an under-addressed component of this disease, which powerfully affects quality of life and limits tolerance to aggressive therapies. In this article, the authors review the current multidisciplinary standards of care in pancreatic cancer with a focus on emerging concepts in pancreatic cancer detection, precision therapy, and survivorship.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020. PMID: 32683683. doi:10.3322/caac.21626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。